A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

Table 2

Univariate and multivariate analyses of overall survival in GSE14520.

Factors	Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)		Hazard ratio (95% CI)
Age (≤50, >50)	1.068 (0.586-1.944)	0.831
Main tumor size (≤5 cm, >5 cm)	1.878 (1.031-3.421)	0.040	1.664 (0.582-4.755)	0.342
Multinodular (yes, no)	1.172 (0.578-2.380)	0.660
Cirrhosis (yes, no)	7.149 (0.983-51.988)	0.052	10.395 (0.669-161.544)	0.094
TNM staging (I, II, and III)	2.923 (1.539-5.551)	0.001	1.212 (0.336-4.369)	0.769
BCLC staging (0 and A, B and C)	2.756 (1.454-5.224)	0.002	0.871 (0.297-2.549)	0.801
AFP (>300 ng/mL, ≤300 ng/mL)	0.721 (0.396-1.313)	0.285
Recurrence months (≤24 months, >24 months)	0.124 (0.057-0.271)	<0.001	0.113 (0.046-0.276)	<0.001
Risk score	3.732 (2.415-5.769)	<0.001	2.109 (1.287-3.455)	0.003